1. Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G. & Sherwood, R. F. (1988). A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700–703.
2. Baxter, L. T., Yuan, F. & Jain, R. K. (1992). Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 52: 5838–5844.
3. Chari, R. V. J., Jackel, K. A., Bourret, L. A., Derr, S. M., Tadayoni, B. M., Mattocks, K. M., Shah, S. A., Liu, C., Blättler, W. A. & Goldmacher, V. S. (1995). Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55: 4079–4084.
4. Chen, B. M., Chan, L. Y., Wang, S. M., Wu, M. F., Chern, J. W. & Roffler, S. R. (1997). Cure of malignant ascites and generation of protective immunity by monoclonal antibody targeted activation of a glucuronide prodrug in rats. Int J Cancer 73: 392–402.
5. Cheng, T. L., Chen, B. M., Chan, L. Y., Wu, P. Y., Chern, J. W. & Roffler, S. R. (1997). Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immun Immunother 44: 305–315.